News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
GlaxoSmithKline (JOBS) to Pay Actelion Ltd. up to $3.3 Billion for Drug Rights
July 14, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - GlaxoSmithKline Ltd could pay Swiss company Actelion Ltd up to 3.3 billion Swiss francs ($3.28 billion) to develop a promising insomnia drug in the largest biotech partnering deal.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Mergers & acquisitions
Europe
MORE ON THIS TOPIC
Layoff Tracker
MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troubles
August 13, 2026
·
83 min read
·
BioSpace Editorial Staff
Rare diseases
Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
August 13, 2026
·
2 min read
·
Tristan Manalac
Bankruptcy
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale
August 13, 2026
·
2 min read
·
Tristan Manalac
Insights
The Italian inflection point: Clinical strength, culture and capital
August 13, 2026
·
1 min read
·
Jennifer C. Smith-Parker
